Abstract:Brain perineuronal nets (PNNs) are vital for neurocircuit stability and changes in their abundance and composition have been linked to Alzheimer's disease (AD) progression. In this work, we investigated age‐associated PNN changes in transgenic mice with tauopathy‐related AD neuropathology. 9‐month‐old PS19 (P301S) mice exhibited changes in PNN chondroitin sulfate‐glycosaminoglycan (CS‐GAG) composition and abundance, but not the underlying CS proteoglycan (CSPG) core proteins, in association with pTau, gliosis, and neurodegeneration. In contrast, Tau4RTg2652 mice showed stable PNNs despite pTau accumulation, emphasizing the importance of neuroinflammation on PNN glycan integrity in AD. Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by clinical symptoms of memory and cognitive deficiencies. Postmortem evaluation of AD brain tissue shows proteinopathy that closely associate with the progression of this dementing disorder, including the accumulation of extracellular beta amyloid (Aβ) and intracellular hyperphosphorylated tau (pTau) with neurofibrillary tangles (NFTs). Current therapies targeting Aβ have limited clinical efficacy and life‐threatening side effects and highlight the need for alternative treatments targeting pTau and other pathophysiologic mechanisms driving AD pathogenesis. The brain's extracellular matrices (ECM), particularly perineuronal nets (PNNs), play a crucial role in brain functioning and neurocircuit stability, and reorganization of these unique PNN matrices has been associated with the progression of AD and accumulation of pTau in humans. We hypothesize that AD‐associated changes in PNNs may in part be driven by the accumulation of pTau within the brain. In this work, we investigated whether the presence of pTau influenced PNN structural integrity and PNN chondroitin sulfate‐glycosaminoglycan (CS‐GAG) compositional changes in two transgenic mouse models expressing tauopathy‐related AD pathology, PS19 (P301S) and Tau4RTg2652 mice. We show that PS19 mice exhibit an age‐dependent loss of hippocampal PNN CS‐GAGs, but not the underlying aggrecan core protein structures, in association with pTau accumulation, gliosis, and neurodegeneration. The loss of PNN CS‐GAGs were linked to shifts in CS‐GAG sulfation patterns to favor the neuroregenerative isomer, 2S6S‐CS. Conversely, Tau4RTg2652 mice exhibit stable PNN structures and normal CS‐GAG isomer composition despite robust pTau accumulation, suggesting a critical interaction between neuronal PNN glycan integrity and neighboring glial cell activation. Overall, our findings provide insights into the complex relationship between PNN CS‐GAGs, pTau pathology, gliosis, and neurodegeneration in mouse models of tauopathy, and offer new therapeutic insights and targets for AD treatment.

The ProNGF/p75NTR pathway induces tau pathology and is a therapeutic target for FTLD-tau

Targeting Tyro3 ameliorates a model of PGRN-mutant FTLD-TDP via tau-mediated synaptic pathology

An Alternative In Vitro Model Of Neurodegeneration In Ftld-U With Pgrn Mutation

Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer’s disease

Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer's disease

O2‐12‐04: Extracellular Domain of P75ntr Attenuates Beta‐amyloid‐induced Neurotoxicity and Tau Hyperphosphorylation

Update on the role of p75NTR in neurological disorders: A novel therapeutic target

Small molecule modulation of the p75 neurotrophin receptor inhibits multiple amyloid beta-induced tau pathologies

Reduction of advanced tau-mediated memory deficits by the MAP kinase p38γ

Tau in neurodegenerative disease

Gfp-Mutant Human Tau Transgenic Mice Develop Tauopathy Following Cns Injections Of Alzheimer'S Brain-Derived Pathological Tau Or Synthetic Mutant Human Tau Fibrils

Perineuronal net deglycosylation associates with tauopathy‐induced gliosis and neurodegeneration

Glymphatic inhibition exacerbates tau propagation in an Alzheimer's disease model

Protein tau phosphorylation in the proline rich region and its implication in the progression of Alzheimer's disease

Effects of P301L-TAU on post-translational modifications of microtubules in human iPSC-derived cortical neurons and TAU transgenic mice

Hyperphosphorylated Tau Relates to Improved Cognitive Performance and Reduced Hippocampal Excitability in the Young rTg4510 Mouse Model of Tauopathy

P75ntr Regulates Aβ Deposition by Increasing Aβ Production but Inhibiting Aβ Aggregation with Its Extracellular Domain

O2-01-05

Neuronal stimulation‐regulated RNA splicing defects in tauopathies are corrected by treatment with a p75 NTR modulator

Update on the Role of P75ntr in Neurological Disorders: A Novel Therapeutic Target.

Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U